New IRAP inhibitors may hold promise for improving cognitive functions in animal models

Researchers have discovered three new inhibitors of insulin-regulated aminopeptidase (IRAP), compounds shown to improve cognitive functions in animal models of human disorders. The new inhibitors are able to block human IRAP at low concentrations with rapid reversibility, as described in a study published in ASSAY and Drug Development Technologies, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the ASSAY and Drug Development Technologies website until July 1, 2016.

In the article "Identification of Drug-Like Inhibitors of Insulin-Regulated Aminopeptidase Through Small Molecule Screening," Karin Engen and coauthors from Uppsala University and Karolinska Institutet (Solna), Sweden, and Vrije Universiteit Brussel, Brussels, Belgium, report on the high throughput screening method they used to test a diverse library of 10,500 compounds for activity against IRAP. The rapid, automated, enzymatic assay led to the identification of 23 active compounds. Rigorous characterization of these actives reduced the number of compounds of particular interest to three, and these served as the starting points for the development of small molecule-based IRAP inhibitors to take into preclinical testing.

"The paper by Engen et al. describes exemplary work successfully executing a carefully planned strategy to identify high-value hits from high-throughput screens," says ASSAY and Drug Development Technologies Editor-in-Chief Andrew D. Napper, PhD, Associate Director, Nemours Center for Childhood Cancer Research, Head - High Throughput Screening/Drug Discovery Laboratory, and Senior Research Scientist, Nemours/A.I. duPont Hospital for Children (Wilmington, DE). "Using high-throughput screening and hit confirmation, the authors identified and efficiently prioritized inhibitors of insulin-regulated aminopeptidase, which hold promise for the improvement of cognitive functions in animal models and advancement into clinical testing."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breakthrough blood test improves early diagnosis of pancreatic cancer